Novartis announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 96 . The study… read more.
UCB, announced that the FDA has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx is the first and only approved… read more.
Roche announced the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of people… read more.
Novartis announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive,… read more.
AbbVie announced the European Commission (EC) granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous… read more.
Merck Inc.,( known as MSD outside of the United States and Canada), announced positive topline results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with… read more.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for LEO Pharma’s Anzupgo (delgocitinib) cream for the treatment of adult patients with moderate to severe… read more.
Coherus BioSciences, Inc. announced that it has entered into an asset purchase agreement dated December 2, 2024, with Intas Pharmaceuticals Ltd. for the divestiture of the Udenyca (pegfilgrastim-cbqv)… read more.
GSK plc and Medicines for Malaria Venture (MMV) announced that the World Health Organization (WHO) has awarded prequalification to tafenoquine, the first single-dose medicine for the prevention of… read more.
Biocon Biologics Ltd , a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced that the FDA has approved Yesintek (ustekinumab-kfce), a biosimilar to the reference… read more.
Zimmer Biomet Holdings, Inc. announced FDA Premarket Approval Application (PMA) Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from… read more.
The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona (elivaldogene autotemcel) and is evaluating the need for “further regulatory… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
